Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000414406 | SCV000490621 | pathogenic | not provided | 2017-01-03 | criteria provided, single submitter | clinical testing | This duplication of one nucleotide in MSH6 is denoted c.3267dupA at the cDNA level and p.Glu1090ArgfsX3 (E1090RfsX3) at the protein level. The normal sequence, with the base that is duplicated in brackets, is TCTT[dupA]GAGC. The duplication causes a frameshift, which changes a Glutamic Acid to an Arginine at codon 1090, and creates a premature stop codon at position 3 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. In addition, MSH6 c.3263dupT, which also results in p.Glu1090ArgfsX3, has been observed in at least one individual with colon cancer (You 2010). Based on currently available evidence, we consider MSH6 c.3267dupA to be pathogenic. |
Myriad Genetics, |
RCV004022153 | SCV004930849 | pathogenic | Lynch syndrome 5 | 2023-12-28 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |